Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Advancing EB06 for Treating Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA ...

Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I ...

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...

The phase 3 AURIGA study evaluated daratumumab (Darzalex) and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma who were in very good partial response, minimal ...

14 The current phase II, dose-ranging, clinical trial was designed to evaluate the efficacy and safety of PF-00547659 in patients with moderate-to-severe CD who have a history of treatment failure or ...

In the open-label phase 2 LITESPARK-003 study, led by Dana-Farber Cancer Institute's Toni Choueiri, MD, researchers investigated for the first time the combination of cabozantinib, an anti-angiogenic ...

Pol. Maj. Gen. Thawatkiat Jindakuansanong, Commander of Chonburi Provincial Police, presided over a meeting to advance “Big ...

Alan W. Dunton, MD, Chief Medical Advisor of Recce Pharmaceuticals, added, “We are thrilled to see such robust clinical results from our Phase II trial. These results demonstrate the potential of ...

The collaboration between Sanofi and Kymera Therapeutics on SAR444656 may represent a significant opportunity for competition ...

Elinzanetant reduced vasomotor symptoms frequency and severity in women with or at high risk of HR-positive breast cancer in ...